OPKO Health Investor Presentation — January 2021

Document content

NASDAQ: OPKJanuary 2021 | 2This presentation contains “forward -looking statements,” asthat term isdefined under thePrivate Securities Litigation Reform Actof1995 (PSLRA), which statements may

beidentified bywords such as“expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” “potential,” and other words of

similar meaning, including statements regarding expected financial performance and expectations regarding themarket forand sales ofourproducts, expectations about

COVID -19testing, thedemand fortesting, ourcapacity fortesting and expected turnaround time, theimpact ofCOVID -19onallofourbusinesses, positively and negatively

thesuccess ofourstrategic ventures, whether theScarlet Health mobile service and theintegrated platform willfunction orperform asdesigned, therole and value ofthe

service topatients and healthcare providers and whether there isademand fortheservice orwhether itwill beavailable, our product development efforts and the

expected benefits ofourproducts, ourestimated revenues and financial projections, whether wewillmaintain profitability orcontinue growth atBioReference, whether

prescriptions forRayaldee willcontinue toincrease, theoutcome ofourclinical trials and validation studies and that such outcomes willsupport marketing approval or

commercialization, theexpected market penetration and size ofthemarket forourproducts, ourability tosuccessfully commercialize ourproduct candidates such ashGH -

CTP, Factor VII-CTP, and our rare disease product candidates, whether Rayaldee will raise serum total 25-hydroxyvitamin D(25D)more effectively than any over -the-

counter (OTC) orprescription (Rx) products currently marketed without theriskofhypercalcemia, ourability todevelop Rayaldee fornew indications including stage 5CKD,

and the timeline fordoing so,whether use ofhGH- CTP inadults and pediatric patients will beapproved, whether wewill berequired tomake any changes toour

development plans forhGH -CTP and increase ourexpenditures, theexpected timing forcommencing, enrolling, completing and announcing results forourclinical trials, the

timing forrelease oftrial data and seeking and obtaining FDA and foreign regulatory approvals aswell asreimbursement coverage forourproducts .These forward -looking

statements areonly predictions and reflect ourviews asofthedate they were made, and weundertake noobligation toupdate such statements .Such statements are

subject tomany risks and uncertainties that could cause our activities oractual results todiffer materially from theactivities and results anticipated inforward looking

statements including thecontinued prevalence ofCOVID -19,developing and obtaining regulatory approvals ofnew, commercially viable and competitive products and